Research on organic solar cells has been conducted for a long time. Recent advancements in understanding their molecular ...

The TOC (Translocon at the Outer envelope of Chloroplasts)-TIC (Translocon at the Inner envelope of Chloroplasts) ...

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

Researchers describe the full molecular structure of the phage DEV. DEV infects and lyses Pseudomonas aeruginosa bacteria, an opportunistic pathogen in cystic fibrosis and other diseases.

As someone who has firsthand experience scaling a company sustainably, I have witnessed the profound impact that the organizational structure can have on long-term success. Through my experiences ...

We used a two-step extraction process to isolate as diverse chemical mixtures as possible," says Georg Braun, postdoctoral researcher in Beate Escher's working group and first author of the study.

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...